All In Biotech

Drug Trial Radar · NCT03587766

Oral Fexinidazole Dosing Regimens for the Treatment of Adults With Chronic Indeterminate Chagas Disease

Phase 2 Randomized, Multicenter, Double-blinded Safety and Efficacy Study to Evaluate Oral Fexinidazole Dosing Regimens for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease

Last checked: Nov 20, 2026Latest source record: Sep 23, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

45

Actual

Start

Nov 13, 2017

Primary completion

Dec 19, 2018

Study completion Aug 28, 2019

Sponsor

Lead sponsor
Drugs for Neglected DiseasesAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 16, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study focuses on the evaluation of low doses (600 and 1200 mg) and short treatment duration (at 3, 7 and 10 days) of fexinidazole (Fexi) to determine the minimal efficacious and safe dose for the treatment of adult patients with chronic indeterminate Chagas Disease (CD).

Conditions

  • Chagas' Disease (Chronic) Nos

Interventions

  • FexinidazoleDrug

    Drug: fexinidazole (FEXI)

  • Placebo Oral TabletDrug

    Drug: fexinidazole

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of adverse events.Time frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital Clinic

    Barcelona, Catalunia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.